Top Analyst Reports for Oracle, Bank of America & McDonald's
https://www.zacks.com/commentary/2274747/top-analyst-reports-for-oracle-bank-of-america-mcdonald-s?cid=CS-ZC-FT-research_daily-2274747
May 16, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Bank of America Corporation (BAC) and McDonald's Corporation (MCD), as well as two micro-cap stocks Miller Industries, Inc. (MLR) and Via Renewables, Inc. (VIA).
0
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
https://www.zacks.com/stock/news/2275062/biotech-stock-roundup-nvax-fulc-up-on-deals-with-sny-updates-from-mrna-bmy?cid=CS-ZC-FT-analyst_blog|stock_roundup-2275062
May 16, 2024 - Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
0
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
https://www.zacks.com/stock/news/2273100/novavax-nvax-q1-earnings-miss-stock-soars-on-sanofi-deal?cid=CS-ZC-FT-analyst_blog|earnings_article-2273100
May 13, 2024 - Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.
0
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
https://www.zacks.com/stock/news/2272917/sanofi-sny-regeneron-s-dupixent-sbla-gets-fda-priority-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2272917
May 13, 2024 - Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
0
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
https://www.zacks.com/stock/news/2262673/astrazeneca-azn-q1-earnings-sales-beat-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2262673
Apr 25, 2024 - AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
0
Sanofi (SNY) Q1 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/04/25/sanofi-sny-q1-2024-earnings-call-transcript/?source=iedfolrf0000001
Apr 25, 2024 - SNY earnings call for the period ending March 31, 2024.
0
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
https://www.zacks.com/stock/news/2260438/sanofi-sny-rilzabrutinib-shows-benefit-in-blood-disorder-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260438
Apr 23, 2024 - Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
0
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
https://www.zacks.com/stock/news/2253429/nurix-nrix-up-on-upbeat-initial-data-from-phase-i-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253429
Apr 10, 2024 - Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
0
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
https://www.zacks.com/stock/news/2239502/regeneron-regn-gets-fda-nod-for-praluent-label-extension?cid=CS-ZC-FT-analyst_blog|earnings_article-2239502
Mar 12, 2024 - Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
0
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
https://www.zacks.com/stock/news/2239307/aslan-asln-up-161-on-upbeat-initial-data-from-eczema-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2239307
Mar 12, 2024 - ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.
0